Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 63

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 63
---
 the extent applicable pursuant to the provisions of the Israeli Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company. As part of the Special Majority vote, you must indicate whether you are a controlling shareholder or have a personal interest in the approval of this proposal. According to the Relief Regulations, by signing and submitting the accompanying proxy card, you declare and approve that you have no personal interest in the approval of this proposal, unless you have notified the Company of such personal interest in writing. If you believe that you have a personal interest in this Proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to Dana Yaacov-Garbeli, our Chief Financial Officer. Board Recommendation The Board recommends that our shareholders vote “FOR” the adoption of this resolution. Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 38

| PROPOSAL THREE — RATIFICATION AND APPROVAL OF REVISED COMPENSATION TERMS TO GREGORY BURSHTEIN, OUR CHIEF OF RESEARCH 
 &DEVELOPMENT                                                                                                         |

Background On April 23, 2025 and April 28, 2025, the Compensation Committee and the Board, respectively, voted to approve revised compensation terms and one-time grant of compensation for Dr. Burshtein in accordance with the terms below, which were deemed by the Board to be outside the range set in the Company’s compensation policy but in line with comparable standards as detailed in the 2025 comparative executive compensation benchmark analyses, which included comparative data of the Company’s executive compensation relative to the peer-group companies in Israel and in the United States. The 2025 comparative executive compensation benchmark analysis found that the compensation terms, especially current annual salary of $160,000, of our Chief of Research & Development are materially below that of similar companies within the market.The update in compensation terms is therefore critical to provide an effective retention incentive. As a result of the conclusions of the 2025 comparative executive compensation benchmark analysis, our Compensation Committee and Board have determined that, it would be advisable for the Company to increase dr. Burshtein’s compensation terms in order to better reflect the terms being offered by companies in a similar sector and of